Abstract
The signaling pathways of TC21-mediated transformation and cell survival are not well-established. In this study, we have investigated the role of PI3-K/Akt signaling pathway in oncogenic-TC21-mediated transformation and cell survival. We found that oncogenic-TC21 stimulated the PI3-K activity. This was associated with the activation of Akt, a key component of PI3-K signaling pathway. We also found that TC21 interacted and formed complex with PI3-K. Mutations in the GTP-binding region of TC21, which enhanced GTP-binding potential of this protein, also stimulated its association with PI3-K, suggesting that PI3-K may preferentially interact with the GTP-bound form. Suppression of PI3-K and Akt by specific inhibitors LY294002 and Wortmannin reversed TC21-induced transformation. Likewise, inhibition of PI3-K activity by the PI3-K phosphotase PTEN reduced TC21-mediated focus formation in NIH3T3 cells. Investigation of TC21's effect on cell survival revealed that mutant-TC21 expressing cells were more resistant to etoposide- and cisplatin-induced cell death, and this was associated with the activation of anti-apoptotic protein NF-κB, a downstream target of Akt. Treatment of PI3-K inhibitor LY294002 significantly suppressed TC21-mediated NF-κB activation. In conclusion, we have identified PI3-K as an effector of TC21 and demonstrated that the PI3-K/Akt signaling pathway plays important roles in TC21-mediated transformation and cell survival.
Similar content being viewed by others
References
Aggarwal BB . 2000 Biochem. Pharmacol. 60: 1003–1009
Auger KR, Carpenter CL, Shoelson SE, Piwnica-Worms H, Cantley LC . 1992 J. Biol. Chem. 267: 5408–5415
Baichwal VR, Baeuerle PA . 1997 Curr. Biol. 7: R94–R96
Bos JL . 1997 Biochem. Biophys. Acta. 1333: M19–M31
Bonneau D, Longy M . 2000 Hum. Mutat. 16: 109–122
Campbell SL, Khosravi-Far R, Rossman KL, Clark GJ, Der CJ . 1998 Oncogene 17: 1395–1413
Cantley LC, Neel B . 1999 Proc. Natl. Acad. Sci. USA 96: 4240–4245
Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF, Stanbridge E, Frisch S, Reed JC . 1998 Science 282: 1318–1321
Chan AM, Miki T, Meyers KA, Aaronson SA . 1994 Proc. Natl. Acad. Sci. USA 91: 7558–7562
Chen C, Edelstein LC, Gelinas C . 2000 Mol. Cell Biol. 20: 2687–2695
Chang HW, Aoki M, Fruman D, Auger KR, Bellacosa A, Tsichlis PN, Cantley LC, Roberts TM, Vogt PK . 1997 Science 276: 1848–1850
Clark GJ, Kinch MS, Gilmer TM, Burridge K, Der CJ . 1996 Oncogene 12: 169–176
Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA . 1995 Nature 378: 785–789
Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME . 1997 Cell. 91: 231–241
Davis RJ . 1995 Mol. Reprod. Dev. 42: 459–467
Downward J . 1998 Curr. Opin. Genet. Dev. 8: 49–54
Drivas GT, Shih A, Coutavas E, Rush MG, D'Eustachio P . 1990 Mol. Cell. Biol. 10: 1793–1798
Dudek H, Datta SR, Franke TF, Birnbaum MJ, Yao R, Cooper GM, Segal RA, Kaplan DR, Greenberg ME . 1997 Science 275: 661–665
Dudley DT, Pang L, Decker SJ, Bridges AJ, Saltiel AR . 1995 Proc. Natl. Acad. Sci. USA 92: 7686–7689
Franke TF, Kaplan DR, Cantley LC . 1997 Cell 88: 435–437
Franke TF, Yang SI, Chan TO, Datta K, Kazlauskas A, Morrison DK, Kaplan DR, Tsichlis PN . 1995 Cell 81: 727–736
Graham SM, Vojtek AB, Huff SY, Cox AD, Clark GJ, Cooper JA, Der CJ . 1996 Mol. Cell. Biol. 16: 6132–6140
Graham SM, Cox AD, Drivas G, Rush MG, D'Eustachio P, Der CJ . 1994 Mol. Cell. Biol. 14: 4108–4115
Graham SM, Oldham SM, Martin CB, Drugan JK, Zohn IE, Campbell S, Der CJ . 1999 Oncogene 18: 2107–2116
Huang Y, Saez R, Chao L, Santos E, Aaronson SA, Chan AM . 1995 Oncogene 11: 1255–1260
Huang Y, Hutter D, Liu Y, Wang X, Liy Y, Sheikh MS, Chan A-M-L, Holbrook NJ . 2000 J. Biol. Chem. 275: 18234–18242
Hu Q, Klippel A, Muslin AJ, Fantl WJ, Williams LT . 1995 Science 268: 100–102
Hutter D, Chen P, Barnes J, Liu Y . 2000 Biochem J. 15: 352 Pt 1 155–163
Kimmelman A, Tolkacheva T, Lorenzi MV, Osada M, Chan AM . 1997 Oncogene 15: 2675–2685
Johnson GL, Garrington TP . 1999 Curr. Opin. Cell Biol. 11: 211–218
Joneson T, Bar-Sagi D . 1997 J. Mol. Med. 75: 587–593
Karin M . 1999 J. Biol. Chem. 274: 27339–27342
Kane LP, Shapiro VS, Stokoe D, Weiss A . 1999 Curr. Biol. 9: 601–604
Leevers SJ, Vanhaesebroeck B, Waterfield MD . 1999 Curr. Opin. Cell. Biol. 11: 219–225
Li ZW, Chu W, Hu Y, Delhase M, Derrinck T, Ellisman M, Johnson R, Karin M . 1999 J. Exp. Med. 189: 1839–1845
Lowe DG, Goeddel DV . 1987 Mol. Cell. Biol. 7: 2845–2856
Lowy DR . 1993 Annu. Rev. Biochem. 62: 851–891
Maehama T, Dixon JE . 1998 J. Biol. Chem. 273: 13375–13378
Marais R, Marshall CJ . 1996 Cancer Survey 27: 101–125
Marte BM, Downward J . 1997 Trends Biochem. Sci. 22: 355–358
Matsumoto K, Asano T, Endo T . 1997 Oncogene 15: 2409–2417
Muise-Helmericks RC, Grimes HL, Bellacosa A, Malstrom SE, Tsichlis PN, Rosen N . 1998 J. Biol. Chem. 273: 29864–29872
Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, Donner DB . 1999 Nature 401: 82–85
Reif K, Burgering BM, Cantress DA . 1997 J. Biol. Chem. 272: 14426–14433
Rodriguez-Viciana P, Warme P, Dhang R, Vanhaessebroeck B, Gout I, Fry M, Waterfield M, Downward J . 1994 Nature 370: 527–532
Rodriguez-Viciana P, Warme P, Vanhaesebroeck B, Waterfield M, Downward J . 1996 EMBO J. 15: 2442–2451
Romashkova L, Makarov SS . 1999 Nature 401: 86–90
Rosário M, Paterson HF, Marshall CJ . 1999 EMBO J. 18: 1270–1279
Seger R, Krebs EG . 1995 FASEB J. 9: 726–735
Sheng H, Shao J, DuBois RN . 2001 J. Biol. Chem. 276: 14498–14504
Skorski T, Bellacosa A, Nieborowska-Skorska M, Majewski M, Martinez R, Choi JK, Trotta R, Wlodarski P, Perrotti D, Chan TO, Wasik MA, Tsichlis PN, Calabretta B . 1997 EMBO J. 16: 6151–6161
Stambolic V, de la Suzuki A, Pompa JL, Brothers GM, Mirtsos C, Sasaki T, Ruland J, Penninger JM, Siderovski DP, Mak TW . 1998 Cell 95: 29–39
Tolias KF, Cantley LC, Carpenter CL . 1995 J. Biol. Chem. 270: 17656–17659
Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin Jr AS . 1998 Science 281: 1680–1683
Wang CY, Guttridge DC, Mayo MW, Baldwin Jr AS . 1999 Mol. Cell. Biol. 19: 5923–5929
Wang X, McCullough KD, Franke TF, Holbrook NJ . 2000 J. Biol. Chem. 275: 14624–14631
Wirth T, Baltimore D . 1988 EMBO J. 7: 3109–3113
Woodgett JR, Avruch J, Kyriakis J . 1996 Cancer Surv. 27: 127–138
Zundel W, Giaccia A . 1998 Genes Dev. 12: 1941–1946
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Rong, R., He, Q., Liu, Y. et al. TC21 mediates transformation and cell survival via activation of phosphatidylinositol 3-kinase/Akt and NF-κB signaling pathway. Oncogene 21, 1062–1070 (2002). https://doi.org/10.1038/sj.onc.1205154
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1205154
- Springer Nature Limited
Keywords
This article is cited by
-
Overexpression of wild type RRAS2, without oncogenic mutations, drives chronic lymphocytic leukemia
Molecular Cancer (2022)
-
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity
Nature Biotechnology (2016)
-
Contribution of the R-Ras2 GTP-binding protein to primary breast tumorigenesis and late-stage metastatic disease
Nature Communications (2014)
-
R-RAS2 overexpression in tumors of the human central nervous system
Molecular Cancer (2013)
-
Thymoquinone and cisplatin as a therapeutic combination in lung cancer: In vitro and in vivo
Journal of Experimental & Clinical Cancer Research (2010)